Tenax Therapeutics (TENX) Competitors $6.26 +0.06 (+0.97%) Closing price 04:00 PM EasternExtended Trading$6.31 +0.05 (+0.80%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TENX vs. PLRX, VTYX, ARTV, CRBU, IFRX, ATOS, ORMP, IZTC, CRDL, and OPTNShould you be buying Tenax Therapeutics stock or one of its competitors? The main competitors of Tenax Therapeutics include Pliant Therapeutics (PLRX), Ventyx Biosciences (VTYX), Artiva Biotherapeutics (ARTV), Caribou Biosciences (CRBU), InflaRx (IFRX), Atossa Therapeutics (ATOS), Oramed Pharmaceuticals (ORMP), Invizyne Technologies (IZTC), Cardiol Therapeutics (CRDL), and OptiNose (OPTN). These companies are all part of the "pharmaceutical products" industry. Tenax Therapeutics vs. Pliant Therapeutics Ventyx Biosciences Artiva Biotherapeutics Caribou Biosciences InflaRx Atossa Therapeutics Oramed Pharmaceuticals Invizyne Technologies Cardiol Therapeutics OptiNose Pliant Therapeutics (NASDAQ:PLRX) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings. Do analysts prefer PLRX or TENX? Pliant Therapeutics currently has a consensus target price of $13.31, suggesting a potential upside of 793.46%. Tenax Therapeutics has a consensus target price of $18.00, suggesting a potential upside of 187.54%. Given Pliant Therapeutics' higher possible upside, equities analysts clearly believe Pliant Therapeutics is more favorable than Tenax Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pliant Therapeutics 0 Sell rating(s) 12 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Tenax Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Which has more risk & volatility, PLRX or TENX? Pliant Therapeutics has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, Tenax Therapeutics has a beta of 2.2, meaning that its stock price is 120% more volatile than the S&P 500. Does the media favor PLRX or TENX? In the previous week, Pliant Therapeutics had 1 more articles in the media than Tenax Therapeutics. MarketBeat recorded 6 mentions for Pliant Therapeutics and 5 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 0.98 beat Pliant Therapeutics' score of 0.21 indicating that Tenax Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pliant Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tenax Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in PLRX or TENX? Tenax Therapeutics received 69 more outperform votes than Pliant Therapeutics when rated by MarketBeat users. However, 63.87% of users gave Pliant Therapeutics an outperform vote while only 55.56% of users gave Tenax Therapeutics an outperform vote. CompanyUnderperformOutperformPliant TherapeuticsOutperform Votes7663.87% Underperform Votes4336.13% Tenax TherapeuticsOutperform Votes14555.56% Underperform Votes11644.44% Do insiders & institutionals have more ownership in PLRX or TENX? 97.3% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 6.4% of Pliant Therapeutics shares are owned by insiders. Comparatively, 3.7% of Tenax Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has stronger valuation & earnings, PLRX or TENX? Tenax Therapeutics has lower revenue, but higher earnings than Pliant Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPliant Therapeutics$1.58M57.75-$161.34M-$3.47-0.43Tenax TherapeuticsN/AN/A-$7.71MN/AN/A Is PLRX or TENX more profitable? Tenax Therapeutics' return on equity of -46.00% beat Pliant Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Pliant TherapeuticsN/A -48.91% -41.09% Tenax Therapeutics N/A -46.00%-42.65% SummaryTenax Therapeutics beats Pliant Therapeutics on 8 of the 15 factors compared between the two stocks. Remove Ads Get Tenax Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TENX vs. The Competition Export to ExcelMetricTenax TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.82M$6.99B$5.68B$8.32BDividend YieldN/A2.72%4.55%4.02%P/E RatioN/A7.2324.5519.25Price / SalesN/A230.77395.7294.09Price / CashN/A65.6738.1634.64Price / Book0.236.617.064.46Net Income-$7.71M$142.13M$3.19B$247.07M7 Day Performance0.16%2.79%1.49%3.05%1 Month Performance6.10%2.70%5.87%-2.85%1 Year Performance69.19%-4.42%14.94%4.63% Tenax Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TENXTenax Therapeutics1.5415 of 5 stars$6.26+1.0%$18.00+187.5%+62.3%$24.82MN/A0.009Earnings ReportUpcoming EarningsNews CoveragePLRXPliant Therapeutics4.5574 of 5 stars$1.59+2.6%$13.31+737.3%-89.1%$97.37M$1.58M-0.4890VTYXVentyx Biosciences2.4267 of 5 stars$1.36+3.0%$10.00+635.3%-79.7%$96.74MN/A-0.5830Positive NewsARTVArtiva BiotherapeuticsN/A$3.91-8.4%$21.00+437.1%N/A$94.97M$2.60M0.0081Analyst ForecastNews CoverageCRBUCaribou Biosciences2.7518 of 5 stars$1.02-1.9%$10.33+913.1%-80.5%$94.87M$9.99M-0.62100IFRXInflaRx2.4577 of 5 stars$1.41+10.2%$8.00+467.4%-5.4%$94.66M$165,789.00-1.3160Earnings ReportHigh Trading VolumeATOSAtossa Therapeutics1.0659 of 5 stars$0.75-0.5%$7.00+833.3%-55.1%$94.35MN/A-3.418News CoverageGap UpORMPOramed Pharmaceuticals1.2703 of 5 stars$2.34+0.4%N/A-19.6%$94.33M$1.34M21.2710Positive NewsIZTCInvizyne TechnologiesN/A$14.81-1.9%N/AN/A$92.59MN/A0.00N/ACRDLCardiol Therapeutics2.1197 of 5 stars$1.12flat$8.40+650.0%-24.3%$92.52MN/A-2.8720News CoverageOPTNOptiNose2.2999 of 5 stars$9.17+0.2%$9.00-1.9%-62.5%$92.25M$75.67M-2.18190High Trading Volume Remove Ads Related Companies and Tools Related Companies Pliant Therapeutics Alternatives Ventyx Biosciences Alternatives Artiva Biotherapeutics Alternatives Caribou Biosciences Alternatives InflaRx Alternatives Atossa Therapeutics Alternatives Oramed Pharmaceuticals Alternatives Invizyne Technologies Alternatives Cardiol Therapeutics Alternatives OptiNose Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TENX) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenax Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenax Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
